← Back to all trials
Recruiting
NCT07288515
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
Conditions: Chronic Lymphocytic Leukemia
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 50
Sponsor: AstraZeneca
Location: Research Site Minsk
Summary
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years.
* Confirmed diagnosis of CLL.
* Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation.
* Treatment-naïve or R/R CLL.
* Ability and willingness to provide informed consent for study participation.
Exclusion Criteria:
* Patients not satisfying any of the inclusion criteria.
* Prior treatment with any BTK inhibitor.
* Participation in other ongoing clinical trials.
* Pregnant or breastfeeding females
Source: ClinicalTrials.gov (NCT07288515). StuddyBuddy aggregates publicly available trial information.
